Literature DB >> 11094626

Autoimmune and inherited subepidermal blistering diseases: advances in the clinic and the laboratory.

E Schmidt1, D Zillikens.   

Abstract

Anchoring complexes are specialized focal attachment sites within the cutaneous basement membrane zone (BMZ) and play a crucial role in dermo-epidermal adhesion. Structural weakness that may be caused by the binding of autoantibodies to components of the anchoring complex or by aberrant expression of these components as a result of genetic defects can lead to subepidermal blisters. Autoimmune subepidermal blistering disorders include bullous pemphigoid, pemphigoid gestationis, lichen planus pemphigoides, linear IgA disease, cicatricial pemphigoid, anti-p200, anti-p105, and anti-p450 pemphigoid, epidermolysis bullosa acquisita, and bullous systemic lupus erythematosus. The autoantigen in the skin of patients with dermatitis herpetiformis remains to be identified. More than 300 distinct mutations in 10 different genes corresponding to structural components of the BMZ have been described that result in skin fragility and dermo-epidermal separation associated with characteristic extracutaneous manifestations. This group of genodermatoses, collectively referred to as epidermolysis bullosa (EB), consists of distinct variants, such as EB simplex, EB with muscular dystrophy, EB with pyloric atresia, generalized atrophic benign EB, Herlitz junctional EB, and dystrophic EB. Recent advances in the molecular characterization of BMZ components have led to a better understanding of the interaction between these molecules as well as the autoimmune response against these proteins. In addition, by the elucidation of genetic defects in the different variants of EB, genotype-phenotype correlations now begin to arise and genetic counseling has been improved.

Entities:  

Mesh:

Year:  2000        PMID: 11094626

Source DB:  PubMed          Journal:  Adv Dermatol        ISSN: 0882-0880


  10 in total

1.  The IL-8 release from cultured human keratinocytes, mediated by antibodies to bullous pemphigoid autoantigen 180, is inhibited by dapsone.

Authors:  E Schmidt; S Reimer; N Kruse; E B Bröcker; D Zillikens
Journal:  Clin Exp Immunol       Date:  2001-04       Impact factor: 4.330

Review 2.  Complement and cutaneous autoimmune blistering diseases.

Authors:  Elizabeth Lessey; Ning Li; Luis Diaz; Zhi Liu
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

3.  [Generalized inflammatory epidermolysis bullosa acquisita initially diagnosed as viral exanthem: a rare disease within the subepidermal blistering disorders].

Authors:  N El-Haj; C Micheli; M Brunner; D Zillikens; C C Zouboulis
Journal:  Hautarzt       Date:  2014-12       Impact factor: 0.751

4.  The pathophysiology of autoimmune blistering diseases.

Authors:  Kim B Yancey
Journal:  J Clin Invest       Date:  2005-04       Impact factor: 14.808

5.  Induction of dermal-epidermal separation in mice by passive transfer of antibodies specific to type VII collagen.

Authors:  Cassian Sitaru; Sidonia Mihai; Christoph Otto; Mircea T Chiriac; Ingrid Hausser; Barbara Dotterweich; Hitoshi Saito; Christian Rose; Akira Ishiko; Detlef Zillikens
Journal:  J Clin Invest       Date:  2005-04       Impact factor: 14.808

Review 6.  Rituximab in treatment-resistant autoimmune blistering skin disorders.

Authors:  Enno Schmidt; Eva-Bettina Bröcker; Matthias Goebeler
Journal:  Clin Rev Allergy Immunol       Date:  2008-02       Impact factor: 8.667

7.  Prothrombotic state and impaired fibrinolysis in bullous pemphigoid, the most frequent autoimmune blistering disease.

Authors:  A V Marzano; A Tedeschi; I Polloni; C Crosti; M Cugno
Journal:  Clin Exp Immunol       Date:  2013-01       Impact factor: 4.330

8.  Collagens are functional, high affinity ligands for the inhibitory immune receptor LAIR-1.

Authors:  Robert Jan Lebbink; Talitha de Ruiter; Jelle Adelmeijer; Arjan B Brenkman; Joop M van Helvoort; Manuel Koch; Richard W Farndale; Ton Lisman; Arnoud Sonnenberg; Peter J Lenting; Linde Meyaard
Journal:  J Exp Med       Date:  2006-06-05       Impact factor: 14.307

Review 9.  [Mucous membrane pemphigoid with ocular involvement. Part I: Clinical manifestations, pathogenesis and diagnosis].

Authors:  E Schmidt; T Meyer-Ter-Vehn; D Zillikens; G Geerling
Journal:  Ophthalmologe       Date:  2008-03       Impact factor: 1.174

10.  Follicular helper T Cells (Tfh) and IL-21 involvement in the pathogenesis of bullous pemphigoid.

Authors:  Qiuju Li; Zhenfeng Liu; Erle Dang; Liang Jin; Zheng He; Luting Yang; Xiaowei Shi; Gang Wang
Journal:  PLoS One       Date:  2013-07-05       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.